China Kangtai Cactus Biotech Inc. ("China Kangtai") (OTCBB: CKGT), a vertically integrated grower, developer, manufacturer and marketer of a variety of cactus-based products in China, announced today that the company has launched a new nutraceutical product, "Cactus Zhi Kang."

Prior to the full launch of Cactus Zhi Kang, the company began marketing trials at the end of 2011 that showed excellent acceptance from consumers. The new nutraceutical product is expected to generate approximately US $2.5 to $3.0 million in sales in 2012.

The new product, which blends cactus with other Chinese herbal ingredients in tablet form, contains several vitamins and minerals such as vitamin C and vitamin E, which are associated with reduced cholesterol and lipoprotein levels. Research has indicated that reduced cholesterol and lipoprotein levels can help reduce problems associated with thrombus, arteriosclerosis, fatty liver and cardiovascular disease.

China Kangtai CEO Jinjiang Wang said, "The new cactus based Nutraceutical product demonstrates our research capability and our ability to develop new products popular with consumers that will help further penetrate the enormous Chinese herbal medicine market. In some areas of Asia, 80% of the population depends on traditional medicine for primary health care. The demand of herbal medicine continues to grow rapidly in China. We believe that our new product 'Cactus Zhi Kang' will be accretive to earnings and will further contribute to an increase in shareholder value."

In the first nine months of 2011, nutraceuticals represented nearly 39% of total company sales. During that period, sales of nutraceuticals rose 30% from $8.7 million to $11.4 million.

About China Kangtai Cactus Biotech, Inc.

China Kangtai Cactus Biotech, Inc. is a leading grower, developer, producer, and marketer of cactus-derived products, including nutraceuticals, health and energy drinks, wine, extracts and powders, cigarettes and animal feed. China Kangtai controls over 387 acres of plants and maintains an active R&D group that holds 18 product patents and is seeking another 12. China Kangtai's high-quality "green" products are sold throughout China via a distribution network that covers 12 of China's 23 provinces and two of China's four municipalities. More information may be found at http://www.biocactus.com or via e-mail: chinakangtai@gmail.com.

China Kangtai's online investor kit, including an investment profile, press releases, current price quotes, stock charts and more is available at http://www.hawkassociates.com/profile/ckgt.cfm. To subscribe to future releases via e-mail alert, visit http://www.hawkassociates.com/about/alert/.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product demand and acceptance, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Hawk Associates
Investor Contacts:
Frank Hawkins or Amy Lin, 305-451-1888
kangtai@hawkassociates.com